
pmid: 18493222
ABSTRACTLabel claims on probiotic products often do not represent the true constituents. With the increased use of probiotics in clinical studies, it is necessary to know the true composition of probiotic products to better interpret study outcomes. We used terminal restriction fragment length polymorphism analysis to rapidly determine the overall bacterial composition of 14 commercial probiotic products and validated the results with species‐specific polymerase chain reaction. The results show that many probiotic products contain unadvertised additional lactobacilli and bifidobacteria, whereas others are missing species listed on the product label. In summary, terminal restriction fragment length polymorphism is a rapid method for profiling the microbial contents of probiotic products used in clinical studies.
Lactobacillus, RNA, Bacterial, Species Specificity, Food Labeling, Probiotics, RNA, Ribosomal, 16S, Dietary Supplements, Bacillus, Bifidobacterium, Polymorphism, Restriction Fragment Length
Lactobacillus, RNA, Bacterial, Species Specificity, Food Labeling, Probiotics, RNA, Ribosomal, 16S, Dietary Supplements, Bacillus, Bifidobacterium, Polymorphism, Restriction Fragment Length
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 53 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
